Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP) — PAMCap  

Breast Cancer Clinical Trial

Official title: Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCap)

Status Completed

Clinical Trial Summary

This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.

Clinical Trial Description

Study will be conducted for 12 weeks (+/-14 days) of monitoring.

BASELINE ASSESSMENTS Baseline assessment should be performed within 14 days of Week 1.

1. Signed informed consent;

2. ECOG Performance Status per treating physician (chart abstraction of available data);

3. Pathology report confirming cancer diagnosis;

4. Psychosocial assessment questionnaires;

5. Blood for correlative biomarkers (10 ml);

6. Documentation of planned/ongoing chemotherapy regimen

ON-STUDY ASSESSMENTS

1. Physical Activity Monitor (PAM)

1. Fitbit (PAM) devices will be provided by investigators for the period of the study;

2. Introduction to the device and instructions on use and care will be provided based on commercial marketing material;

3. Subjects will be assisted in setting up Fitbit device on smart phone;

4. Subjects will be asked to wear Fitbit device continuously for 12 weeks - however, the device should not be worn during bathing or showering;

5. Subjects will be asked to sync their Fitbit devices to the database at least once a week;

6. Clinical coordinator may send phone or text reminders to encourage syncing as Fitbit device can only record 1 weeks' worth of data;

7. Cost Coverage

8. Investigators will purchase devices prior to start of study with grant funding.

9. PAM Accountability

10. Investigator and investigator site are responsible for maintaining accurate inventory and accountability logs for the devices.

11. Subjects will be asked to sign a form upon receipt and return of device as applicable.

2. ECOG - Eastern Cooperative Oncology Group Performance Status 0 - Fully active, able to carry on all pre-disease performance without restriction; 1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 - Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 - Completely disabled -- cannot carry on any self-care. Totally confined to bed or chair; 5 - Dead

3. Functional Assessment of Cancer Therapy - General (FACT-G).

a. The FACT-G is a 27-item scale designed to measure multidimensional quality of life in breast cancer patients.

4. Quick Inventory of Depressive Symptomatology - Self-Rated (QIDS-SR116) .

a. The QIDS-SR16 is a 16-item version of the 30-item Inventory of Depressive Symptomatology (IDS) designed to assess severity of depression-specific symptoms.

5. Pittsburgh Sleep Quality Index (PSQI) (See Appendix H).9

a. The PSQI is a 19-item scale designed to assess sleep quality and disturbances.

6. Brief Fatigue Inventory (BFI) (See Appendix I).10

a. The BFI is a 9-item scale designed to assess fatigue in cancer patients.

7. Biomarker and DNA Blood Tests

1. Blood samples will be collected at each study visit indicated by the study calendar. Process samples according to the sample processing instructions. Prior to storage, complete the sample inventory logs for each subject so that specimen chain of custody can be established. Samples will be frozen at −80°C until the time of analysis;

2. Include in each shipment batch copies of: 1) the blood collection source documents for each patient; and 2) copies of each subjects specimen inventory form;

3. Keep originals of these documents in the subject's chart;

4. Samples will be analyzed using a multiplexed ELISA method (Meso Scale Discovery) for IL-1beta, IL-6, IL-10 and TNF-alpha;

5. With explicit participant consent, samples will also be processed for DNA and stored for future analysis. ;

Related Conditions & MeSH terms

• Breast Cancer
• Endocrine Cancer
• Endocrine Gland Neoplasms
• Gastrointestinal Cancer
• Gastrointestinal Neoplasms
• Genitourinary Cancer
• Gynecologic Cancer
• Leukemia
• Lung Cancer
• Male Genital Cancer
• Skin Cancer
• Skin Neoplasms
• Urogenital Neoplasms

• NCT number: NCT02583815
• Study type: Observational
• Source: University of Texas Southwestern Medical Center
• Status: Completed
• Start date: August 2015
• Completion date: September 15, 2017